Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck Enters License Agreement with Jiangsu Hengrui Pharmaceuticals

What are you searching for?

Sign in
Collaborations & Alliances

Merck Licenses Lp(a) Inhibitor from Hengrui Pharma

Merck will manufacture and commercialize HRS-5346 worldwide.

By: Rachel Klemovitch

Assistant Editor

Merck and Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, have entered an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 trial in China in adults with elevated Lp(a) at high risk for cardiovascular events.

Under the agreement, Merck has exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the Greater China region. Hengrui Pharma will receive an upfront payment of $200 million and is eligible to receive milestone payments associated with certain development, regulatory, and commercial milestones up to $1.77 billion, as well as royalties on net sales of HRS-5346.

Dr. Dean Y. Li, president of Merck Research Laboratories, said, “HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition that expands and complements our cardio-metabolic pipeline.”

The transaction is expected to close in the second quarter of 2025.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics